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Allografting induces persistent molecular remissions (MR) in multiple myeloma (MM). We here present the 
results of minimal residual disease (MRD) analyses by nested qualitative PCR (Nested-PCR) and real time 
quantitative (RQ)–PCR in 26 patients (pts) with stage II-III MM treated with a tandem auto-allo approach. 
Transplants consisted of an autograft followed by non-myeloablative 200 cGy TBI and an allograft. BM 
samples were collected at diagnosis, after the autograft, at month 1, 3, 6 after the allograft and then every 
6 months. Nested-PCR and RQ-PCR analyses were carried out using patient-specific primers as previously 
described (Voena, Leuk 1997; Ladetto, BBMT 2000). For outcome analysis pts were grouped according to 
reported criteria (Ladetto, ASH 2011): FullMR and StandardMR indicated MRD negativity on two 
consecutive samples by nested-PCR or by RQ-PCR respectively. Nineteen/26 pts had a molecular marker. At 
a median follow-up of 10,5 years (5,2-13,9) from diagnosis and 9,9 years (4,2-12,9) from the allograft, 
overall survival (OS) was 61% and median  progression-free survival was 5,2 years. Transplant-related 
mortality occurred in 3/19 pts (16%), while 5/19 pts (26%) died of disease progression. Overall, cumulative 
incidence of non-relapse mortality (NRM) was 16%. MRD analysis showed that after the autograft 3/19 pts 
(16%) were negative by nested-PCR. After the allograft, the rate of PCR negativity remained low at month 1 
(3/19, 16%) and 3 (5/19, 26%). However, PCR negativity went up to 44% (8/18) at 6 months and 47% (7/15) 
at one year post-transplant. Overall, 8 pts achieved FullMR at a median time from allograft of 6 months (1-
12) and for a median duration of 33 months (6-102). Overall, 8 relapses occurred, 6 among 11 pts who 
never achieved FullMR and 2 in 8 pts who reached FullMR. Of these one has incomplete follow up and in 
the other one clinical relapse was heralded by a molecular relapse. Pts in FullMR had lower relapse 
incidence (27% vs 55% p=0,189) and better median OS (not reached vs p=0,027)) than pts who did not 
achieve FullMR . StandardMR occurred in 12/19 pts (63%) during the first 24 months post-transplant, at a 
median time of 2 months (1-18) and for a median duration of 27 months (3-102). Pts in StandardMR 
showed lower relapse incidence (RI) (27% vs 71% p=0,016) and better median OS (not reached vs p=0,05) 
as compared to pts with positive PCR. 
